Status:
TERMINATED
Sitagliptin in Cystic Fibrosis-Related Diabetes
Lead Sponsor:
University of British Columbia
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the dipeptidyl peptidase IV (DPPIV) inhibitor sitagliptin is effective in the treatment of cystic fibrosis-related diabetes (CFRD). We hypothesize tha...
Detailed Description
To date, no clinical trials have been conducted using the DPPIV inhibitor sitagliptin in cystic fibrosis-related diabetes. Cystic fibrosis-related diabetes is characterized initially by post-prandial ...
Eligibility Criteria
Inclusion
- 19 years of age or older
- Cystic fibrosis-related diabetes with or without fasting hyperglycemia either untreated or using only pre-prandial repaglinide or pre-prandial bolus insulin therapy
Exclusion
- Age under 19 years
- Use of basal insulin therapy
- Creatinine Clearance \< 50 mL/min
- Active cystic fibrosis exacerbation
- Pregnancy
- Women of child-bearing age not using effective contraception
- Current or prior use of DPPIV inhibitor
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT01257464
Start Date
September 1 2010
End Date
June 1 2012
Last Update
March 6 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of British Columbia Gerontology & Diabetes Reserach Centre (ViTALITY)
Vancouver, British Columbia, Canada, V5Z 1L8